Hepatocyte-specific deletion of Alkbh5 improves glucose tolerance and mitigates metabolic dysfunction-associated fatty liver disease (MAFLD) in obesity by inhibiting GCGR–cyclic adenosine monophosphate (cAMP) and EGFR–PI3K–AKT–mTORC1 signaling. The gene discussed is ALKBH5; the disease is fatty liver disease.